The Worldwide Human Microbiome Industry is Projected to Reach $3.7 Billion by 2027 – ResearchAndMarkets.com

The Worldwide Human Microbiome Industry is Projected to Reach $3.7 Billion by 2027 – ResearchAndMarkets.com




The Worldwide Human Microbiome Industry is Projected to Reach $3.7 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Human Microbiome Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The Global Human Microbiome Market is projected to reach USD 3,724.81 million by 2027 from USD 1,053.28 million in 2021, at a CAGR 23.43% during the forecast period.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

  • The Americas Human Microbiome Market size was estimated at USD 421.10 million in 2021, is expected to reach USD 516.80 million in 2022, and is projected to grow at a CAGR of 23.48% to reach USD 1,492.84 million by 2027.
  • The Asia-Pacific Human Microbiome Market size was estimated at USD 268.32 million in 2021, is expected to reach USD 332.21 million in 2022, and is projected to grow at a CAGR of 23.83% to reach USD 967.77 million by 2027.
  • The Europe, Middle East & Africa Human Microbiome Market size was estimated at USD 363.85 million in 2021, is expected to reach USD 442.02 million in 2022, and is projected to grow at a CAGR of 23.06% to reach USD 1,264.18 million by 2027.

Market Segmentation & Coverage:

The report on human microbiome identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making.

This market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

This research report categorizes the human microbiome to forecast the revenues and analyze the trends in each of the following sub-markets:

Disease:

  • Acute Diarrhea
  • Autoimmune Disorders
  • Cancer
  • Diabetes
  • Mental Disorders
  • Obesity

Technology:

  • 16s rRNA Sequencing
  • Cell Culture Technology
  • Computational Tools
  • High-Throughput Technology
  • Metagenomic Sequencing
  • Omics Technology

Product:

  • Diagnostic Devices
  • Drugs
  • Foods
  • Prebiotic & Probiotics

Therapeutic Area:

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Skin Disorders
  • Women’s Health

Application:

  • Diagnostics
  • Therapeutics

Region:

  • Americas

    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
  • Asia-Pacific

    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
  • Europe, Middle East & Africa

    • France
    • Germany
    • Italy
    • Netherlands
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • United Arab Emirates
    • United Kingdom

Company Usability Profiles:

  • 4D pharma PLC
  • AOBiome, LLC
  • Astarte Medical Partners, Inc
  • Axial Therapeutics, Inc.
  • DuPont de Nemours, Inc.
  • Enterome Bioscience
  • Evelo Biosciences, Inc.
  • Exeliom Biosciences SAS
  • Ferring B.V.
  • Finch Therapeutics Group, Inc.
  • Intralytix, Inc.
  • Locus Biosciences, Inc.
  • Merck and Co. Inc.
  • Metabiomics Corporation
  • Osel Inc.
  • Second Genome, Inc.
  • Seres Therapeutics, Inc.
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Yakult Honsha Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/bzz4be

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900